[go: up one dir, main page]

DK1090033T3 - Partikler af HCV-kappeproteiner: Anvendelse til vaccination - Google Patents

Partikler af HCV-kappeproteiner: Anvendelse til vaccination

Info

Publication number
DK1090033T3
DK1090033T3 DK99929306T DK99929306T DK1090033T3 DK 1090033 T3 DK1090033 T3 DK 1090033T3 DK 99929306 T DK99929306 T DK 99929306T DK 99929306 T DK99929306 T DK 99929306T DK 1090033 T3 DK1090033 T3 DK 1090033T3
Authority
DK
Denmark
Prior art keywords
hcv
vaccination
particles
proteins
envelope proteins
Prior art date
Application number
DK99929306T
Other languages
English (en)
Other versions
DK1090033T4 (da
Inventor
Erik Depla
Geert Maertens
Alfons Bosman
Wijnendaele Frans Van
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26152268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1090033(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of DK1090033T3 publication Critical patent/DK1090033T3/da
Publication of DK1090033T4 publication Critical patent/DK1090033T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK99929306T 1998-06-24 1999-06-23 Partikler af HCV-kappeproteiner: Anvendelse til vaccination DK1090033T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98870142 1998-06-24
EP99870033 1999-02-22
PCT/EP1999/004342 WO1999067285A1 (en) 1998-06-24 1999-06-23 Particles of hcv envelope proteins: use for vaccination

Publications (2)

Publication Number Publication Date
DK1090033T3 true DK1090033T3 (da) 2005-04-25
DK1090033T4 DK1090033T4 (da) 2008-03-31

Family

ID=26152268

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99929306T DK1090033T4 (da) 1998-06-24 1999-06-23 Partikler af HCV-kappeproteiner: Anvendelse til vaccination

Country Status (20)

Country Link
US (3) US6635257B1 (da)
EP (2) EP1090033B2 (da)
JP (1) JP2002518037A (da)
KR (1) KR100559096B1 (da)
CN (1) CN1313864A (da)
AT (1) ATE286067T1 (da)
AU (1) AU765940B2 (da)
BR (1) BR9911397A (da)
CA (1) CA2330526A1 (da)
DE (1) DE69922958T3 (da)
DK (1) DK1090033T4 (da)
ES (1) ES2237115T5 (da)
HU (1) HU227275B1 (da)
IL (2) IL140217A0 (da)
NZ (2) NZ528952A (da)
PL (1) PL201679B1 (da)
PT (1) PT1090033E (da)
RU (1) RU2247729C2 (da)
TR (1) TR200003843T2 (da)
WO (1) WO1999067285A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185061A1 (en) * 1994-07-29 2004-09-23 Innogenetics N.V. Redox reversible HCV proteins with native-like conformation
KR100559096B1 (ko) * 1998-06-24 2006-03-15 인노제네틱스 엔. 브이. Ｈｃｖ 피막 단백질 입자 및 그의 백신접종용 용도
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
DE60043708D1 (de) * 1999-10-13 2010-03-04 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen
CA2411575C (en) * 2000-06-08 2015-04-07 Walter Schmidt Immunostimulatory oligodeoxynucleotides
US20030191291A1 (en) * 2000-09-08 2003-10-09 Kochendoerfer Gerd G. Synthetic erythropoiesis stimulating proteins
AU2001292667A1 (en) * 2000-09-13 2002-03-26 Hawaii Biotechnology Group, Inc. Immunogenic composition of hepatitis c and methods of use thereof
US7101561B2 (en) * 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
EP1381671A2 (en) 2001-04-24 2004-01-21 Innogenetics N.V. Constructs and methods for expression of recombinant hcv envelope proteins
GB0114629D0 (en) * 2001-06-15 2001-08-08 Pfizer Ltd Method
AU2002361160B2 (en) * 2001-12-18 2008-07-03 Genimmune N.V. Purified Hepatitis C virus envelope proteins for diagnostic and therapeutic use
US20040126395A1 (en) * 2001-12-18 2004-07-01 Geert Maertens Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
FR2839722A1 (fr) 2002-05-17 2003-11-21 Bio Merieux Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
JP2004085528A (ja) * 2002-07-05 2004-03-18 Kansai Tlo Kk 拡散定数変化による蛋白質の会合検出方法及び装置
CA2499580A1 (en) 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
EP1852441B1 (en) * 2002-09-24 2012-03-28 The Burnham Institute Agents that modulate EPH receptor activity
EP1481985A1 (en) * 2003-05-28 2004-12-01 Innogenetics N.V. Modified hepatitis C virus (HCV) NS3 for medical treatment
EP1561470A1 (en) * 2003-06-20 2005-08-10 Innogenetics N.V. HCV vaccines comprising the envelope-1 (E1) protein or the corresponding DNA and at least one antiviral agent
CN1889963A (zh) * 2003-10-10 2007-01-03 宝德杰克特疫苗有限公司 方法
WO2006070028A1 (es) * 2004-12-23 2006-07-06 Berthet Francois Xavier Composiciones y procedimientos para detectar infección patógena
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
EP1574517A1 (en) * 2004-03-09 2005-09-14 Innogenetics N.V. HCV E1 comprising specific disulfide bridges
WO2006033012A2 (en) * 2004-09-24 2006-03-30 Pfizer Limited Method of screening for modulators of hepatitis c virus infection
DE102004057111A1 (de) 2004-11-26 2006-06-01 Niles-Simmons Industrieanlagen Gmbh Verfahren zum Zwischenbearbeiten von Wellen
CN101146822A (zh) 2005-01-27 2008-03-19 伯纳姆研究所 EphB受体结合肽
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
EP2004684A4 (en) * 2006-03-22 2009-05-06 Genimmune N V THE HEPATITIS C-VIRUS NEUTRALIZING ANTIBODIES
RU2329303C2 (ru) * 2006-08-02 2008-07-20 Государственное учреждение Научно-исследовательский институт вирусологии им. Д.И. Ивановского Российской академии медицинских наук Моноклональное антитело, иммунореактивное с белком нуклеокапсида (кор) вируса гепатита с-4g5, способ диагностики вгс-инфекции и комбинация моноклональных антител для его осуществления
WO2009131681A2 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
WO2010052214A2 (en) * 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Novel method
BR112013032675A2 (pt) * 2011-06-19 2017-08-08 Vaxine Pty Ltd composição adjuvante de vacina compreendendo partículas de inulina
JP6567824B2 (ja) * 2011-10-12 2019-08-28 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
RU2510998C2 (ru) * 2012-08-01 2014-04-10 Николай Николаевич Грановский ВАКЦИНА НА ОСНОВЕ ВИРУСОПОДОБНЫХ ЧАСТИЦ, СОДЕРЖАЩИХ ВСЕ СТРУКТУРНЫЕ АНТИГЕНЫ ВИРУСА ГЕПАТИТА С, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ В ДРОЖЖАХ Hansenula polymorpha
KR20150130438A (ko) 2013-03-12 2015-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 인간 파밀로마 바이러스용 개선된 백신 및 이것을 사용하는 방법
AU2017332854B2 (en) 2016-09-21 2024-11-14 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
JP6795468B2 (ja) * 2017-07-14 2020-12-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
JP7075130B2 (ja) * 2019-10-25 2022-05-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395395A (en) * 1979-05-21 1983-07-26 The United States Of America As Represented By The Department Of Health And Human Services Detection of non-A, non-B hepatitis associated antigen
RU2175657C2 (ru) * 1990-11-08 2001-11-10 Чирон Корпорейшн Асиалогликопротеин вируса гепатита c (нсv), иммуногенная композиция, способ индукции иммунного ответа, способ иммуноанализа
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
EP0992580B1 (en) * 1993-11-04 2005-03-09 Innogenetics N.V. Immunodominant human T-cell epitopes of Hepatitis C virus
BR9506059A (pt) * 1994-07-29 1997-10-28 Innogenetics Nv Proteinas envelopes purificadas de virus c para uso de diagnóstico e terapêutico
AU702436B2 (en) * 1994-10-21 1999-02-18 Innogenetics N.V. New sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
ATE423204T1 (de) * 1996-11-08 2009-03-15 Us Gov Health & Human Serv Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln
DK1471074T3 (da) * 1998-04-17 2008-11-17 Innogenetics Nv Fremgangsmåder til forbedring af konformationen af proteiner ved hjælp af reduktionsmidler
KR100559096B1 (ko) * 1998-06-24 2006-03-15 인노제네틱스 엔. 브이. Ｈｃｖ 피막 단백질 입자 및 그의 백신접종용 용도

Also Published As

Publication number Publication date
IL140217A (en) 2009-09-22
KR20010053181A (ko) 2001-06-25
US20030202987A1 (en) 2003-10-30
JP2002518037A (ja) 2002-06-25
EP1090033B2 (en) 2007-12-19
AU765940B2 (en) 2003-10-02
TR200003843T2 (tr) 2001-06-21
PT1090033E (pt) 2005-05-31
IL140217A0 (en) 2002-02-10
CN1313864A (zh) 2001-09-19
HK1037639A1 (en) 2002-02-15
HUP0102478A3 (en) 2004-10-28
ES2237115T3 (es) 2005-07-16
NZ528952A (en) 2004-09-24
DK1090033T4 (da) 2008-03-31
DE69922958T3 (de) 2008-06-26
PL345018A1 (en) 2001-11-19
PL201679B1 (pl) 2009-04-30
HU227275B1 (en) 2011-01-28
CA2330526A1 (en) 1999-12-29
RU2247729C2 (ru) 2005-03-10
EP1090033A1 (en) 2001-04-11
NZ508797A (en) 2004-02-27
KR100559096B1 (ko) 2006-03-15
BR9911397A (pt) 2002-01-15
HUP0102478A2 (hu) 2001-10-28
US6635257B1 (en) 2003-10-21
ATE286067T1 (de) 2005-01-15
EP1090033B1 (en) 2004-12-29
DE69922958D1 (de) 2005-02-03
US20060275323A1 (en) 2006-12-07
WO1999067285A1 (en) 1999-12-29
ES2237115T5 (es) 2008-05-16
AU4615299A (en) 2000-01-10
DE69922958T2 (de) 2006-03-30
EP1555270A1 (en) 2005-07-20

Similar Documents

Publication Publication Date Title
DK1090033T3 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
EP1200109A4 (en) USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
BR9814487A (pt) "vacina"
DE58906121D1 (de) Rekombinantes Vaccinia-Virus MVA.
MA24638A1 (fr) Vaccin
ATE405647T1 (de) Rekombinantes gelatin in impstoffen
EE200200709A (et) Liitvalku sisaldava kompositsiooni ning seda liitvalku ja liitpolüpeptiidi kodeeriva nukleiinhappe kasutamine
NO20001768D0 (no) Viruskapsomervaksine, fremgangsmåte til fremstilling samt anvendelse derav
WO2005013918A3 (en) Compositions, methods and kits relating to poxvirus subunit vaccines
CA2505942A1 (en) West nile virus vaccine
AU2002220460A1 (en) The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits
NZ518999A (en) Vaccine compositions
BRPI0113155B8 (pt) métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b
AU2001290178A1 (en) A hepatitis c virus non-structural ns3/4a fusion gene
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
ATE469170T1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
WO2000012535A3 (en) Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
DE60231475D1 (de) Materialien und methoden zur behandlung von hepatitis c
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
BR0112020A (pt) Partìculas tipo vìrus de bvdv
DE69736779D1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
DK1423525T3 (da) Rekombinant MVA, der kan eksprimere HCV-strukturantigener
ATE381351T1 (de) Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten
TR200202169T1 (tr) Tanı ve tedavide kullanım için pürifiye hepatit C virüsü zarf proteinleri.
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof